CFO of Marin County's Ultragenyx Pharmaceutical announces departure

The "Follow This Story" feature will notify you when any articles related to this story are posted.

When you follow a story, the next time a related article is published — it could be days, weeks or months — you'll receive an email informing you of the update.

If you no longer want to follow a story, click the "Unfollow" link on that story. There's also an "Unfollow" link in every email notification we send you.

This tool is available only to subscribers; please make sure you're logged in if you want to follow a story.

Please note: This feature is available only to subscribers; make sure you're logged in if you want to follow a story.


Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a Novato-based maker of treatments for serious rare and ultrarare diseases, on Tuesday announced that its chief financial officer will be resigning.

Executive Vice President Shalini Sharp plans to step down once a replacement is found or by Sept. 2, the announcement said. She would then stay on for six months to help with the transition.

“This decision is based on my personal desire to spend more time with my family, and I could not be more excited and optimistic about the future of Ultragenyx,” Sharp said in a statement. Focusing more time on her advisory role on the boards of directors at other biotechnology companies was another reason given for her planned departure.

The company CEO praised Shalini’s financial and strategic leadership as “a pillar of our tremendous progress.”

“She joined as our first finance employee in 2012 and has successfully managed our financing through going public and beyond, as well as represented the company to investors,” said Emil D. Kakkis, M.D., Ph.D., CEO and President. “We are extremely grateful for her contributions in growing Ultragenyx from a small private company to a global, publicly-traded, biopharmaceutical company with multiple approved therapies and a robust pipeline. As she moves toward her transition, Shalini has put us in a strong financial position to continue to execute on our vision to bring therapies to patients with limited options.”

Sharp joined Ultragenyx in 2012 and is responsible for the company’s finance, investor relations, strategic planning, and information technology functions. She also serves on the board of directors of Neurocrine Biosciences, Sutro Biopharma, Precision Biosciences, and the TB Alliance.

On Feb. 14, the company reported that its net loss more than doubled to $402.7 million, or $7.12 per share, from a year before. But revenue doubled over the year, to $103.7 million, from $51.5 million.

News of Sharp’s resignation parallels an announcement from another Marin County maker of treatments for rare diseases. San Rafael-based BioMarin Pharmaceutical on Feb. 3 said Dan Spiegelman is exiting as of Sept. 1 after 17 years with the company.

Show Comment

Our Network

Santa Rosa Press Democrat
Sonoma Index-Tribune
Petaluma Argus Courier
Sonoma Magazine
Bite Club Eats
La Prensa Sonoma
Emerald Report
Spirited Magazine